Expertise in
9
conditions

Dr. Melvin Heyman

Pediatric Gastroenterology
Office
5565 W Las Positas Blvd Ste 140, 
Pleasanton, CA 
Expertise in
9
conditions
Office
5565 W Las Positas Blvd Ste 140, 
Pleasanton, CA 

Overview

Melvin Heyman is a Pediatric Gastroenterologist in Pleasanton, California. Dr. Heyman is highly rated in 9 conditions, according to our data. His top areas of expertise are Childhood Pancreatitis, Chronic Pancreatitis, Viral Gastroenteritis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 140 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatric Gastroenterology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Office
5565 W Las Positas Blvd Ste 140, Pleasanton, CA 94588

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

140 Total Publications

Parents with physical disabilities and their parenting experiences: a scoping review of qualitative studies.
Parents with physical disabilities and their parenting experiences: a scoping review of qualitative studies.
Journal: Disability and rehabilitation
Published: August 25, 2025
Similar Doctors
Paul Harmatz
Expertise in
12
conditions
Dr. Paul Harmatz
Pediatric Gastroenterology
Expertise in
12
conditions
Dr. Paul Harmatz
Pediatric Gastroenterology

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (11.6 miles away)
510-428-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Paul Harmatz is a Pediatric Gastroenterologist who specializes in mucopolysaccharidoses (MPS) and other lysosomal storage diseases. He is the Medical Director of the Pediatric Clinical Research Program in Mucopolysaccharidoses (MPS) and Related Disorders at UCSF Benioff Children's Hospital. Dr. Harmatz has been the Principal Investigator on multiple clinical trials involving MPS and its variants. He is licensed to practice in CA. Dr. Harmatz is highly rated in 12 conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), and Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome).

Expertise in
6
conditions
Dr. Sohail Husain
Pediatric Gastroenterology
Expertise in
6
conditions
Dr. Sohail Husain
Pediatric Gastroenterology

Office

750 Welch Rd Ste 116, 
Palo Alto, CA 
 (27.3 miles away)
650-498-5605
Languages Spoken:
English
See accepted insurances

Sohail Husain is a Pediatric Gastroenterologist in Palo Alto, California. Dr. Husain is highly rated in 6 conditions, according to our data. His top areas of expertise are Childhood Pancreatitis, Hereditary Pancreatitis, Acute Pancreatitis, Endoscopy, and Gallbladder Removal.

Expertise in
5
conditions
Dr. Zachary Sellers
Pediatric Gastroenterology
Expertise in
5
conditions
Dr. Zachary Sellers
Pediatric Gastroenterology

Office

750 Welch Rd Ste 116, 
Palo Alto, CA 
 (27.3 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Zachary Sellers is a Pediatric Gastroenterologist in Palo Alto, California. Dr. Sellers is highly rated in 5 conditions, according to our data. His top areas of expertise are Childhood Pancreatitis, Chronic Pancreatitis, Hereditary Pancreatitis, Exocrine Pancreatic Insufficiency, and Gallbladder Removal.

Frequently Asked Questions about Dr. Melvin Heyman

How do I make an appointment with Dr. Melvin Heyman?

You can book an appointment with Dr. Melvin Heyman by calling their office at 925-598-3500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Melvin Heyman a top-rated expert for Childhood Pancreatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Melvin Heyman is classified as an Elite expert for Childhood Pancreatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Melvin Heyman specialize in?

While Dr. Melvin Heyman is a Pediatric Gastroenterology, they have specific expertise in Childhood Pancreatitis, Chronic Pancreatitis, and Viral Gastroenteritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Gastroenterology.

Does Dr. Melvin Heyman participate in research or clinical trials?

Yes. Dr. Melvin Heyman has published 140 articles and abstracts on conditions like Childhood Pancreatitis. You can view a list of Dr. Melvin Heyman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Melvin Heyman accept my insurance?

Dr. Melvin Heyman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 925-598-3500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heyman's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile